Usamos cookies para melhorar a sua experiência em nosso site. Se continuar navegando, entendemos que você concorda com estas condições.

We use cookies to improve your experience on our website. If you continue browsing, we understand that you agree to these conditions.

Wir verwenden Cookies, um Ihre Erfahrung auf unserer Website zu verbessern. Wenn Sie weiter surfen, erklären Sie sich mit diesen Bedingungen einverstanden.

Índice de Pesquisa e Desenvolvimento


Prof. Marcos J. Araúzo-Bravo

Scientific Advisor

Electronic and control engineer from the University of Valladolid, Spain; with PhD degree in industrial technologies from the University of Cartagena, and a PhD degree in information technology and biotechnology from the Kyushu Institute of Technology in Iizuka, Japan. He was awarded a 2-year Japan Society-for the Promotion of Science, JSPS postdoctoral research fellowship at the Kyushu Institute of Technology. He led for 7 years the laboratory of Computational Biology and Bioinformatics at the Max Planck Institute for Molecular Biomedicine in Münster, Germany. Since 2014 he is an Ikerbasque Research Professor, head of the group of Computational Biology and Systems Biomedicine and head of the Computational Biomedicine Data Analysis Platform at the Biodonostia Health Research Institute, San Sebastián, Spain. Member of the CIBER network of Frailty and Healthy Ageing (CIBERfes), Madrid, Spain; member of the Thematic Network of Excellence for Transitional Bioinformatics Network (TransBioNet), Barcelona Supercomputing Centre, Spain. Coordinator of the European project 4D-HEALING: Data-Driven Drug Discovery for Wound Healing (ERACoSysMed call 2017). Principal investigator of FET European proyect CIRCULAR VISION: Circular DNA in diagnosis and disease models. He develops Big Data approaches for integrating omics, image and clinical history data to study the interaction of biological networks in terms of their topology, dynamics, and perturbations to interpret complex biological systems associated with neurodegenerative diseases, cancer, aging, stem cells and regenerative medicine. His vast experience analyzing and deriving models from omics data, especially epigenomics, produced more than 140 publications, many of them with very high impact such as Science, Nature, Nature Cell Biology, Cell, and Journal of the American Chemical Society.